ESMO Breast 2022 | Findings indicate HER2-low and HER2-negative breast cancer are biology indistinct

Benedetta Conte, IDIBAPS, Barcelona, Spain talks on the role of HER2-low breast cancer. Findings presented at the European Society of Medical Oncology (ESMO) Breast Cancer 2022 meeting indicate HER2-low and HER2-negatve breast cancer are not biologically distinct entities. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.